The Evaluation of Effect of Aurora Kinase Inhibitor CCT137690 in Melanoma and Melanoma Cancer Stem Cell


Sogutlu F., Kayabasi C., Yelken B. O. , AŞIK A. , Gasimli R., Kipcak S., ...More

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.21, no.12, pp.1564-1574, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 12
  • Publication Date: 2021
  • Doi Number: 10.2174/1871520620666201026155101
  • Title of Journal : ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
  • Page Numbers: pp.1564-1574

Abstract

Background: Dysregulation of the cell cycle is one of the main causes of melanomagenesis. Genomewide studies showed that the expression of Aurora-A and-B significantly has been upregulated in melanoma. However, there is no FDA approved drug targeting aurora kinases in the treatment of melanoma. In addition, the development of resistance to chemotherapeutic agents in the treatment of melanoma and, as a result, the relapse due to heterogeneous cell groups in patients is a second phenomenon that causes treatment failure. Therefore, there is an urgent need for therapeutic alternatives targeting both melanoma and melanoma cancer stem cells (MCSCs) in treatments. At this stage, cell cycle regulators become promising targets.